These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2821181)

  • 21. Cell-mediated immunity to varicella-zoster virus infection in strain 2 guinea pigs.
    Jenski L; Myers MG
    J Med Virol; 1987 Sep; 23(1):23-30. PubMed ID: 2824676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine.
    Sharp M; Terada K; Wilson A; Nader S; Kinchington PE; Ruyechan WT; Hay J; Arvin AM
    J Infect Dis; 1992 May; 165(5):852-8. PubMed ID: 1314871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed-type hypersensitivity and in vitro lymphocyte response in guinea pigs immunized with a live varicella vaccine.
    Shiraki K; Yamanishi K; Takahashi M; Dohi Y
    Biken J; 1984 Mar; 27(1):19-22. PubMed ID: 6091616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine.
    Diaz PS; Smith S; Hunter E; Arvin AM
    J Immunol; 1989 Jan; 142(2):636-41. PubMed ID: 2536059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralization epitope of varicella zoster virus on native viral glycoprotein gp118 (VZV glycoprotein gpIII).
    Montalvo EA; Grose C
    Virology; 1986 Mar; 149(2):230-41. PubMed ID: 2418586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection.
    Schub D; Janssen E; Leyking S; Sester U; Assmann G; Hennes P; Smola S; Vogt T; Rohrer T; Sester M; Schmidt T
    J Infect Dis; 2015 Feb; 211(4):600-12. PubMed ID: 25180236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination.
    Jenkins DE; Yasukawa LL; Bergen R; Benike C; Engleman EG; Arvin AM
    J Immunol; 1999 Jan; 162(1):560-7. PubMed ID: 9886433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune response to varicella-zoster virus glycoproteins in guinea pigs infected with Oka varicella vaccine.
    Sato H; Kageyama S; Imakita M; Ida M; Yamamura J; Kurokawa M; Shiraki K
    Vaccine; 1998 Aug; 16(13):1263-9. PubMed ID: 9682389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen.
    Sauerbrei A; Wutzler P
    J Clin Microbiol; 2006 Sep; 44(9):3094-7. PubMed ID: 16954232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin (IL)-10, IL-12, and interferon-gamma production in primary and memory immune responses to varicella-zoster virus.
    Jenkins DE; Redman RL; Lam EM; Liu C; Lin I; Arvin AM
    J Infect Dis; 1998 Oct; 178(4):940-8. PubMed ID: 9806019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity in mice of varicella-zoster virus glycoprotein I expressed by a vaccinia virus-varicella-zoster virus recombinant.
    Ludvíková V; Kunke D; Hamsíková E; Kutinová L; Vonka V
    J Gen Virol; 1991 Jun; 72 ( Pt 6)():1445-9. PubMed ID: 1646285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of lymphocytes by varicella-zoster virus (VZV): expression of interleukin-2 receptors on lymphocytes cultured with VZV antigen.
    Ito M; Nakano T; Kamiya T; Kitamura K; Komada Y; Ihara T; Kamiya H; Sakurai M
    J Infect Dis; 1992 Jan; 165(1):158-61. PubMed ID: 1309371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection.
    Arvin AM; Koropchak CM; Williams BR; Grumet FC; Foung SK
    J Infect Dis; 1986 Sep; 154(3):422-9. PubMed ID: 3016110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine.
    Vafai A
    Vaccine; 1995 Oct; 13(14):1336-8. PubMed ID: 8585290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Varicella immunity: persistent serologic non-response to immunization.
    Katial RK; Ratto-Kim S; Sitz KV; Moriarity R; Engler RJ
    Ann Allergy Asthma Immunol; 1999 May; 82(5):431-4. PubMed ID: 10353572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination.
    Ludwig B; Kraus FB; Allwinn R; Keim S; Doerr HW; Buxbaum S
    Infection; 2006 Aug; 34(4):222-6. PubMed ID: 16896582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell surface expression of the varicella-zoster virus glycoproteins and Fc receptor.
    Litwin V; Sandor M; Grose C
    Virology; 1990 Sep; 178(1):263-72. PubMed ID: 2167554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allotype analysis to distinguish the origin of varicella-zoster virus immunoglobulin G after allogeneic stem cell transplantation.
    Yamazaki R; Nakasone H; Tanaka Y; Sato M; Terasako K; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Ashizawa M; Machishima T; Kimura S; Kikuchi M; Okuda S; Kako S; Kanda J; Tanihara A; Nishida J; Kanda Y
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1013-20. PubMed ID: 23583826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians.
    Ogunjimi B; Smits E; Heynderickx S; Van den Bergh J; Bilcke J; Jansens H; Malfait R; Ramet J; Maecker HT; Cools N; Beutels P; Van Damme P
    Clin Vaccine Immunol; 2014 Mar; 21(3):417-26. PubMed ID: 24429070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen.
    Shiraki K; Hayakawa Y; Mori H; Namazue J; Takamizawa A; Yoshida I; Yamanishi K; Takahashi M
    J Gen Virol; 1991 Jun; 72 ( Pt 6)():1393-9. PubMed ID: 1646279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.